CARB-X

?? NEW CARB-X funding round! CARB-X is pleased to announce our 2025 funding round, seeking #therapeutics for infections caused by Gram-negative pathogens and #diagnostics for typhoid fever for low-resource settings. We encourage applicants from around the globe to apply. Target product profiles and minimal entry criteria for each theme will be available on carb-x.org. Expressions of interest may be submitted from 16 April 2025 at 10:00 ET – 30 April 2025 at 23:59 ET. A second cycle will open in the later months of 2025. Recent estimates show that a regular release of new, potent antibiotics targeting Gram-negative bacteria, which is part of CARB-X’s mission, could avert 11.1 million cumulative deaths caused by antimicrobial resistance in the coming 25 years, with the largest reductions in low-and-middle-income countries (LMICs) in regions including South Asia, Southeast Asia, East Asia and Oceania, and sub-Saharan Africa. Typhoid fever is a severe systemic illness caused by the Gram-negative S. typhi. Each year, there are between 11 and 21 million cases of typhoid fever, with the greatest burden among children and adults living in LMICs in South Asia, and Southeast Asia and sub-Saharan Africa. The illness is responsible for approximately 128,000 to 161,000 deaths globally. "Although progress has been made in the discovery and early development of therapeutics addressing various AMR challenges, there is broad agreement that we still need a new antibiotic, particularly an orally available one, with broad-spectrum activity against Gram-negative pathogens,” said Erin Duffy, Ph.D., R&D Chief of CARB-X. “At the same time, fast, affordable, and accessible diagnostics for S. typhi are essential to improve early detection and treatment. CARB-X is committed to addressing these pressing challenges by issuing strategic, targeted funding solicitations to accelerate innovative science for antibacterial products.” Two public webinars will be held during the week of 14 April 2025 to discuss the scope of the funding round, application process, and to answer questions. ?? Read the full announcement to learn about the two funding themes, eligibility criteria, and more: bit.ly/4k8Z5uC ?? Sign up for the CARB-X newsletter to receive updates about webinars, target product profiles, and minimal entry criteria: bit.ly/42hkl #AMR #AntibioticResistance #StopSuperBugs #GlobalHealth #Medicine #DrugDevelopment #AntibioticDevelopment #AntibioticFunding #TyphoidFever

Join CARB-X at The Microbiome Times Partnering Forum, hosted in collaboration with European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group in Brussels, Belgium! CARB-X Alliance Director Trudy Grossman and Vedanta Biosciences, Inc. Biosciences Senior Director of Research and Development Greg Medlock will be presenting their talk, “Synergizing Innovation: Advancements in Microbiome-Based Anti-Infectives, from Vedanta Biosciences and CARB-X.” ?? Tuesday, March 18 ? 9:40 – 10 AM GMT ?? Register here: bit.ly/3Fao3cW #Microbiome #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology ?

In a new study, BU researchers found that bacteria exposed to microplastics became resistant to multiple types of antibiotics commonly used to treat infections. Here's what this could mean ??

This Saturday marks International Women's Day. To recognise and celebrate the many contributions by women across sectors to the urgent global challenge of antimicrobial resistance, the Fleming Initiative is teaming up with Australia's National Science Agency, CSIRO, to launch a ‘Trailblazers in AMR’ programme. This year, its focus will be on women trailblazers whose pioneering work is helping us tackle this crisis. The Fleming Initiative and CSIRO are delighted that Access to Medicine Foundation, AMR Insights, CARB-X, One Health Trust, and WHO Collaborating Centre on AMR at University Melbourne are joining the ‘Trailblazers in AMR’ programme as initial nominating organisations. Learn more ?? https://lnkd.in/gJaFbTUM Featured image: Photograph of a laboratory technician (1965), credit to the Centers for Disease Control and Prevention. #InternationalWomensDay #amr #antimicrobialresistance #antibioticresistance

???????????????? ???????????????????????? ?????????????? ?????????? ???????????????? ??????????????????, ?????? ?????????????????????????????????? ?????????????????? ???? ????????-???????????????? ?????????????????? ???????????????????? We're pleased to announce we have selected the lead candidate in our ABX-01 programme, to progress into first-in-human clinical studies. Based on our Alphamer? immunotherapy platform, the compound is a broad-spectrum antimicrobial peptide specifically selected to combat clinically prevalent and multidrug-resistant Gram-negative bacterial strains, to expand therapeutic options for even the most vulnerable patients. ?? Jennifer Schneider, Centauri's CEO, said: "We are excited to enter the clinical development phase with the ABX-01 lead candidate, thanks to our dedicated team who have worked hard to advance our Alphamer platform to this crucial stage. The platform has the potential to address a vital gap in the current anti-infective treatment landscape, and we remain confident that our lead candidate will continue to demonstrate this as we progress towards a Phase I clinical trial. We are proud to progress this molecule with the continuous support of our investors and our long-standing partner, CARB-X, for which we are grateful.” Read the full press release: https://lnkd.in/eB-s-RQn

?? Save the date! CARB-X is proud to sponsor the Global AMR Innovators’ Conference (GAMRIC), a new event connecting researchers, academics, and industry professionals from around the world to share insights about product development to address antimicrobial resistance (AMR). This science-focused meeting will feature plenaries, panels, and posters across the pillars of treatments, preventatives, and diagnostics. ?? Tuesday, Sept. 30 – Thursday, Oct. 2, 2025 ?? Washington DC, USA GAMRIC is a further development of the fall scientific meeting formerly known as ASM-ESCMID. The program and registration information will be available in the coming weeks. Stay tuned! Thank you to our fellow sponsors LifeArc, ESCMID - European Society of Clinical Microbiology and Infectious Diseases, Global Antibiotic R&D Partnership (GARDP), BEAM Alliance, and AMR.Solutions. We are excited to launch GAMRIC to foster innovation and collaboration to address AMR. #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #Innovation #Biotechnology #AntibioticDevelopment #DrugDevelopment #GAMRIC

We are excited and humbled that Forbes India has chosen Bugworks Research Inc. as the best Emerging Innovator of India 2025 in the deep science space. At a gala awards function last night in Mumbai, our cofounders Anand Anandkumar, Bala Subramanian? and Santanu Datta? were on stage to receive this prestigious award. Our gratitude and thanks to our funders, collaborators, business partners and well wishers for their continued support and belief in our team’s journey to tackle two major health challenges shaping humanity - Antimicrobial Resistance and Cancer. This accolade will accelerate our mission to make a difference in the lives of needy patients. Biotechnology Industry Research Assistance Council (BIRAC) CARB-X Centre for Cellular and Molecular Platforms (C-CAMP) Lightrock India Global Antibiotic R&D Partnership (GARDP) UTEC - The University of Tokyo Edge Capital Partners Global Brain Corporation 3one4 Capital Kotak Alternate Asset Managers Limited Kiran Mazumdar Shaw Aquipharma

CARB-X Chief of Research and Development Erin Duffy introduced the funding themes for CARB-X's new funding round today at the 9th AMR Conference, hosted by BEAM Alliance and bamconn GmbH in Basel, Switzerland! ?? Learn more about the funding round, its themes, and timeframes to apply here: bit.ly/4k8Z5uC #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #Innovation #Biotechnology #AMRConference #AntibioticDevelopment #DrugDevelopment #AntibioticFunding #TyphoidFever

Antibiotic resistance has become one of our most pressing health challenges. To address this global health issue, Kinvard Bio, a startup out of the Myers Lab at Harvard University, is developing a new class of antibiotics that target drug-resistant infections and diseases. Their innovative approach holds promise for overcoming pre-existing resistance, offering hope for effective treatments against a broad range of pathogens. While at the Myers Lab, the research team received funding and support from the Blavatnik Biomedical Accelerator and CARB-X. Kineticos Life Sciences provided support through its AMR Accelerator Fund I to launch the company. Co-founders Ben Tresco and Kelvin Wu, former graduate students in the Myers Lab who led the research, joined CEO Lloyd Payne at Kinvard to advance the innovations. Kinvard Bio is focused on acute and chronic drug-resistant infections, including bacterial pneumonia, complicated urinary tract infections, and chronic respiratory infections, with both intravenous and oral formulations. These advancements aim to enhance treatment efficacy and reduce hospital stays, minimizing the risk of acquiring secondary infections. https://lnkd.in/ezUdvMp7 #translationalresearch #universitystartup #Harvardstartup #BlavatnikBiomedicalAccelerator

?? Exciting News! ?? We are proud to announce that CARB-X is awarding $2 million to IMMUNETHEP to support the development of our conjugated peptide-based vaccine against invasive Escherichia coli infections! ?? With no existing vaccine for E. coli, this funding will help us advance our platform technology to induce robust and long-lasting immunity, addressing a critical unmet medical need. E. coli is a major cause of bloodstream infections, sepsis, meningitis, and other life-threatening conditions, particularly in vulnerable populations. The rise of antibiotic-resistant strains further underscores the urgency of developing effective preventive solutions. We are grateful to CARB-X for their support and confidence in our innovative approach. Together, we are taking a significant step forward in the fight against E. coli infections and antimicrobial resistance. ?? Let’s work together to drive innovation in infectious disease prevention! #Immunethep #CARBX #AMR #Biotech #Vaccines #InfectiousDiseases #PublicHealth